News
-
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
-
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
-
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
-
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
-
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb
-
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
-
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
-
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
-
Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease
-
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease
-
Zenas BioPharma Appoints Dr. John Orloff to Board of Directors
-
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
-
Zenas BioPharma Announces New Executive Leadership Appointments
-
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
